复方卡托普利(Captopril/Hydrochlorothiazide) - 药物靶点：ACE x NCC_在研适应症：高血压_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Compound Captopril、卡托普利/氢氯噻嗪、Capozide

+ [2]

靶点

ACE x NCC

作用机制

ACE抑制剂(血管紧张素转化酶抑制剂)、NCC抑制剂(噻嗪类敏感氯化钠协同转运蛋白抑制剂)

治疗领域

心血管疾病

在研适应症

高血压

非在研适应症-

原研机构

Bristol Myers Squibb Co.

在研机构

常州制药厂有限公司

非在研机构

Apothecon LLC

最高研发阶段批准上市

首次获批日期

美国 (1984-10-12),

高血压

最高研发阶段(中国)批准上市

特殊审评-

登录后查看时间轴

结构

分子式C16H23ClN4O7S3

InChIKeySFIUYASDNWEYDB-HHQFNNIRSA-N

CAS号110075-07-5

关联

2

项与复方卡托普利相关的临床试验

NCT04964050 / Withdrawn临床1期

An Open-label, Randomized Three Period, Three Sequence, Partially Replicated Crossover Bioequivalence Study of Two Oral Formulations of Captopril/Hydrochlorothiazide 50/25 mg Tablets in Healthy Adult Participants Under Fasting Conditions

This is a bioequivalence study to compare Capozide (test product [T]) to ACE-Hemmer-ratiopharm (reference product[R]) produced by Ratiopharm GmbH Germany in healthy adult participants under fasting conditions.
ACE-Hemmer-ratiopharm®is the registered trademark of Ratiopharm GmbH Germany.

开始日期2022-04-21

申办/合作机构

GSK Plc

NCT02217852 / Unknown status临床4期IIT

A Randomized, Open-label, Positive Drug Controlled Clinical Trials to Compare the Efficacy of Nitrendipine and Hydrochlorothiazide , Captopril Plus Hydrochlorothiazide and Beijing Hypotensive No.0 in Tibetan Hypertension

Several surveys had revealed that Tibetan adults had high prevalence of hypertension. However, there was no research studying the antihypertensive effect of the known drugs in Tibetan. The main arms of our study were to determine if the efficacy of lowing blood pressure and protecting target organ damage differs between nitrendipine and Hydrochlorothiazide in mild hypertension in Tibetan, and to determine if the efficacy of lowing blood pressure and protecting target organ damage differs between captopril plus Hydrochlorothiazide and Beijing hypotensive No.0 in moderate and severe Tibetan hypertension.

开始日期2014-08-01

申办/合作机构

四川大学华西医院（四川省国际医院）

100 项与复方卡托普利相关的临床结果

登录后查看更多信息

100 项与复方卡托普利相关的转化医学

登录后查看更多信息

100 项与复方卡托普利相关的专利（医药）

登录后查看更多信息

16

项与复方卡托普利相关的文献（医药）

2005-01-01·Kardiologiia4区 · 医学

[Comparative efficacy of fixed dose combinations of enalapril with hydrochlorothiazide and captopril with hydrochlorothiazide in patients with high risk hypertension].

4区 · 医学

Article

作者: Nedogoda, S V

Clinical effectiveness and tolerability of o.d. use of fixed dose combinations of enalapril (10 mg) with hydrochlorothiazide (25 mg) (Enap H) and captopril (50 mg) with hydrochlorothiazide (25 mg) (Capozide) were compared in a randomized study on 60 patients with I-II degree high and very high risk hypertension. Study duration was 6 months, number of patients in each of parallel groups -- 30. Antihypertensive activity, ability to improve arterial elasticity and T/P parameter, cost/efficacy index of enalapril (10 mg) plus hydrochlorothiazide (25 mg) combination was found to be superior to those of captopril (50 mg) plus hydrochlorothiazide (25 mg) combination.

2005-01-01·Kardiologiia4区 · 医学

[Comparative efficacy of fixed dose combinations of perindopril with indapamide and captopril with hydrochlorothiazide in patients with high risk hypertension].

4区 · 医学

Article

作者: Marchenko, I V ; Prokhorova, E A ; Nedogoda, S V ; Brel', U A ; Tsoma, V V ; Chaliabi, T A

Clinical effectiveness and tolerability of o.d. use of fixed dose combinations of perindopril (4 mg) with indapamide (1.25 mg) (Noliprel forte) and captopril (50 mg) with hydrochlorothiazide (25 mg) (Capozide) were compared in a randomized study on 40 patients with I-II degree high and very high risk hypertension. Study duration was 6 months, number of patients in each of parallel groups -- 20. Antihypertensive activity, ability to decrease left ventricular hypertrophy, to improve arterial elasticity and T/P parameter of perindopril (4 mg) -- indapamide (1.25 mg) combination was found to be superior to those of captopril (50 mg) -- hydrochlorothiazide (25 mg) combination.

2000-06-01·European Journal of Drug Metabolism and Pharmacokinetics4区 · 医学

Liquid extraction and HPLC-DAD assay of hydrochlorothiazide from plasma for a bioequivalence study at the lowest therapeutic dose

4区 · 医学

Article

作者: V. David ; D. S. Miron ; C. Mircioiu ; A. Medvedovici

The main parameters considered in optimizing the liquid extraction and quantitative assay were the yield, precision, limit of quantification, time required for extraction and concentration, and quantity of solvent. The influence on these parameters of the following factors was examined: nature of the extracting solvent, quantity of solvent, co-extraction solvent, and duration of stirring. Instead of equilibrium parameters of the involved thermodynamic system, a kinetic approach was preferred in terms of the effective partition 'constant', which is not really constant but a function of time and extraction conditions. The final selected method, considered to be rapid and simple, was applied to determine the pharmacokinetics of hydrochlorotiazide (HCT) after administration of Capozide (Bristol-Myers Squibb) tablets containing 50 mg Captopril and 25 mg HCT, to 4 healthy volunteers. The results obtained were in accordance with the pharmacokinetic parameters of HCT reported in the literature.

100 项与复方卡托普利相关的药物交易

登录后查看更多信息